Cornelia M.
- Country
- Germany
- Department
- N/A
Research Overview
- Efficacy and safety of zenagamtide versus semaglutide in participants with overweight or obesity and type 2 diabetes
- J2A-MC-GZGQ: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)
- J2A-MC-GZGS: A Phase 3, Open-Label Study of Once Daily Orforglipron Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
Data & Insights
Has run more than one trial at 20 of 204 partner sites.
Specializations
Type 2 Diabetes and Glycaemic Control
Clinical research activity includes therapies for type 2 diabetes mellitus with a strong focus on improving blood glucose control in routine care. The investigator is involved in studies comparing long-acting insulin strategies and other glucose-lowering treatments for adults requiring treatment intensification.
- Type 2 diabetes
- HbA1c reduction
- Basal insulin therapy
Research in this area also addresses treatment options for people with diabetes who have additional metabolic risk factors, supporting advances in practical diabetes management.
Obesity and Overweight
The investigator is actively engaged in clinical studies targeting body weight reduction in adults with overweight or obesity, including populations living with type 2 diabetes. This work reflects a therapeutic interest in pharmacologic management of excess body weight and related metabolic disease.
- Obesity treatment
- Weight loss interventions
- Metabolic disease
These studies contribute to the development of therapies aimed at reducing adiposity and improving cardiometabolic health.
Cardiovascular Disease Risk Reduction
Another major area of interest is the prevention of cardiovascular events in people with type 2 diabetes and excess body weight. The investigator participates in research evaluating treatments designed to lower the occurrence of serious cardiovascular outcomes in high-risk populations.
- Major adverse cardiovascular events
- Cardiovascular safety
- High cardiovascular risk
This area links metabolic therapy with prevention of myocardial infarction, stroke, and related cardiac complications.
Chronic Kidney Disease and Multimorbidity
Clinical trial involvement also extends to patients with chronic kidney disease, reflecting interest in complex metabolic and renal comorbidity. The investigator’s research landscape includes conditions where diabetes, obesity, and kidney disease intersect, requiring therapies with broad cardiometabolic relevance.
- Chronic kidney disease
- Cardiorenal risk
- Multimorbidity
This supports evaluation of treatments for patients with overlapping renal and metabolic disease burdens.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.